IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab

By  

Current Rheumatology Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 288-300

Bentham Science Publishers

Access to resources Recommend Favorite

The OPTION trial: inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis

By Ramos-Remus Cesar   Muriel-Vizcaino Rodolfo  

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 429-434

Future Medicine

Access to resources Recommend Favorite

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

By Hishitani Y   Ogata A   Shima Y   Hirano T   Ebina K   Kunugiza Y   Shi K   Narazaki M   Hagihara K   Tomita T   Yoshikawa H   Tanaka T   Kumanogoh A  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 4, 2013-08 ,pp. : 253-259

Informa Healthcare

Access to resources Recommend Favorite

A case of active rheumatoid arthritis with renal dysfunction treated effectively with tocilizumab monotherapy

By Kato Takashi   Koni Ichiro   Inoue Ryo   Kitajima Susumu   Kawano Mitsuhiro   Yamagishi Masakazu  

Modern Rheumatology, Vol. 20, Iss. 3, 2010-06 ,pp. : 316-318

Springer Publishing Company

Access to resources Recommend Favorite

High Titer of Anticardiolipin Antibody Is Associated with First-Ever Ischemic Stroke in Taiwan

By  

Cerebrovascular Diseases, Vol. 22, Iss. 4, 2006-08 ,pp. : 225-230

Karger

Access to resources Recommend Favorite